These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35786601)

  • 21. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
    Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
    Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites.
    Lu HR; Zeng H; Kettenhofen R; Guo L; Kopljar I; van Ammel K; Tekle F; Teisman A; Zhai J; Clouse H; Pierson J; Furniss M; Lagrutta A; Sannajust F; Gallacher DJ
    Toxicol Sci; 2019 Aug; 170(2):345-356. PubMed ID: 31020317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment and validation of a torsade de pointes prediction model based on human iPSC‑derived cardiomyocytes.
    Pan D; Li B; Wang S
    Exp Ther Med; 2023 Jan; 25(1):61. PubMed ID: 36588805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.
    Huang M; Liao Z; Li X; Yang Z; Fan X; Li Y; Zhao Z; Lang S; Cyganek L; Zhou X; Akin I; Borggrefe M; El-Battrawy I
    Front Pharmacol; 2021; 12():675003. PubMed ID: 34025432
    [No Abstract]   [Full Text] [Related]  

  • 26. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Tanaka K; Takahashi E; Miyamoto K; Morimura K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Shinozawa T; Saito F; Kunimatsu T
    Regul Toxicol Pharmacol; 2017 Aug; 88():238-251. PubMed ID: 28634147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
    Bot CT; Juhasz K; Haeusermann F; Polonchuk L; Traebert M; Stoelzle-Feix S
    J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing proarrhythmic potential of environmental chemicals using a high throughput in vitro-in silico model with human induced pluripotent stem cell-derived cardiomyocytes.
    Lin HC; Rusyn I; Chiu WA
    ALTEX; 2024 Jan; 41(1):37-49. PubMed ID: 37921411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of beating rate control for the analysis of drug effects on contractility in human induced pluripotent stem cell-derived cardiomyocytes.
    Hinata Y; Kagawa Y; Kubo H; Kato E; Baba A; Sasaki D; Matsuura K; Sawada K; Shimizu T
    J Pharmacol Toxicol Methods; 2022; 118():107228. PubMed ID: 36273536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
    Millard D; Dang Q; Shi H; Zhang X; Strock C; Kraushaar U; Zeng H; Levesque P; Lu HR; Guillon JM; Wu JC; Li Y; Luerman G; Anson B; Guo L; Clements M; Abassi YA; Ross J; Pierson J; Gintant G
    Toxicol Sci; 2018 Aug; 164(2):550-562. PubMed ID: 29718449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
    Yamamoto W; Asakura K; Ando H; Taniguchi T; Ojima A; Uda T; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yoshinaga T; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
    PLoS One; 2016; 11(12):e0167348. PubMed ID: 27923051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes].
    Yanagida S; Kanda Y
    Yakugaku Zasshi; 2024; 144(3):265-271. PubMed ID: 38432935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human perinatal stem cell derived extracellular matrix enables rapid maturation of hiPSC-CM structural and functional phenotypes.
    Block T; Creech J; da Rocha AM; Marinkovic M; Ponce-Balbuena D; Jiménez-Vázquez EN; Griffey S; Herron TJ
    Sci Rep; 2020 Nov; 10(1):19071. PubMed ID: 33149250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does Enhanced Structural Maturity of hiPSC-Cardiomyocytes Better for the Detection of Drug-Induced Cardiotoxicity?
    Van de Sande D; Ghasemi M; Watters T; Burton F; Pham L; Altrocchi C; Gallacher DJ; Lu H; Smith G
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
    J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
    Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
    Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. hiPSC-CM electrophysiology: impact of temporal changes and study parameters on experimental reproducibility.
    Guerrelli D; Pressman J; Salameh S; Posnack N
    Am J Physiol Heart Circ Physiol; 2024 Jul; 327(1):H12-H27. PubMed ID: 38727253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A deep learning platform to assess drug proarrhythmia risk.
    Serrano R; Feyen DAM; Bruyneel AAN; Hnatiuk AP; Vu MM; Amatya PL; Perea-Gil I; Prado M; Seeger T; Wu JC; Karakikes I; Mercola M
    Cell Stem Cell; 2023 Jan; 30(1):86-95.e4. PubMed ID: 36563695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Action potential response of human induced-pluripotent stem cell derived cardiomyocytes to the 28 CiPA compounds: A non-core site data report of the CiPA study.
    Yu Y; Zhang M; Chen R; Liu F; Zhou P; Bu L; Xu Y; Zheng L
    J Pharmacol Toxicol Methods; 2019; 98():106577. PubMed ID: 31022455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.